Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088478 · ClinicalTrials.gov registry record · Phase 3
Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 402
- Enrollment target
NCT00088478 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 402 participants.
The verdict
NCT00088478, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 402 participants
- Enrollment target
Study Summary
Key objectives of this clinical study are to: * Determine how well intramuscular (IM) olanzapine depot works compared to placebo * Evaluate the safety and tolerability of IM olanzapine depot compared to placebo * Evaluate different doses of IM olanzapine depot compared to placebo to identify the best dose(s).
Interventions
- DRUG Placebo
- DRUG Intramuscular Olanzapine Depot
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2004-06 |
| Est. Completion | 2005-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088478
The ClinicalTrials.gov registry entry for NCT00088478 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00088478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088478 about?
NCT00088478 is a clinical study titled "Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia". Key objectives of this clinical study are to: * Determine how well intramuscular (IM) olanzapine depot works compared to placebo * Evaluate the safety and tolerability of IM olanzapine depot compared to placebo * Evaluate different doses of IM olanzapine depot compared to placebo to identify the be...
What is the current status of trial NCT00088478?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 402 participants. The study started on 2004-06. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00088478?
The interventions under investigation include: Placebo (DRUG), Intramuscular Olanzapine Depot (DRUG).
Who is sponsoring clinical trial NCT00088478?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.